+Compare
BNTC
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
8.18M

BNTC Benitec Biopharma Forecast, Technical & Fundamental Analysis

a biotechnology, research and development company

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for BNTC with price predictions
07:00 PM EST Dec 07, 2023

BNTC's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for BNTC moved out of overbought territory on November 06, 2023. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 instances where the indicator moved out of the overbought zone. In of the 16 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for BNTC turned negative on November 09, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

BNTC moved below its 50-day moving average on December 05, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BNTC crossed bearishly below the 50-day moving average on November 30, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BNTC broke above its upper Bollinger Band on November 03, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BNTC entered a downward trend on December 08, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 77 cases where BNTC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 07, 2023. You may want to consider a long position or call options on BNTC as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.367) is normal, around the industry mean (20.733). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (19.569) is also within normal values, averaging (330.425).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BNTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 10,162%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 27%. OZYMD experienced the highest price growth at 8,999,901%, while ZVSA experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was 4% and the average quarterly volume growth was 51%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

BNTC is expected to report earnings to rise 1,918.75% to -323 cents per share on September 27

Benitec Biopharma BNTC Stock Earnings Reports
Q2'23
Est.
$-3.23
Q1'23
Beat
by $0.04
Q4'22
Missed
by $0.09
Q3'22
Missed
by $0.28
Q2'22
Missed
by $0.34
The last earnings report on May 15 showed earnings per share of -15 cents, beating the estimate of -20 cents. With 5.05K shares outstanding, the current market capitalization sits at 8.18M.
A.I. Advisor
published General Information

General Information

a biotechnology, research and development company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
3940 Trust Way
Phone
+1 510 780-0819
Employees
18
Web
https://www.benitec.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IHG87.262.99
+3.55%
InterContinental Hotels Group Plc
TITN26.01-0.04
-0.15%
Titan Machinery
GOCO13.98-0.50
-3.45%
GoHealth
TC0.25-0.01
-5.64%
TuanChe Limited
RUN12.89-0.98
-7.07%
Sunrun

BNTC and

Correlation & Price change

A.I.dvisor tells us that BNTC and MLTX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BNTC and MLTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTC
1D Price
Change %
BNTC100%
-2.10%
MLTX - BNTC
29%
Poorly correlated
+0.27%
CMMB - BNTC
27%
Poorly correlated
+2.06%
TCON - BNTC
25%
Poorly correlated
-5.85%
APLMW - BNTC
24%
Poorly correlated
-4.44%
FATE - BNTC
24%
Poorly correlated
-4.68%
More

Groups containing BNTC

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTC
1D Price
Change %
BNTC100%
-2.10%
australia
(undefined stocks)
13%
Poorly correlated
-4.54%
drugs
(undefined stocks)
7%
Poorly correlated
-0.70%
biotechnology
(undefined stocks)
7%
Poorly correlated
-1.09%